James J. Harding, MD

James J. Harding, MD, discusses efficacy data with nivolumab plus ipilimumab that led to this regimen’s FDA approval for unresectable or metastatic hepatocellular carcinoma

Dr Harding discusses the significance of the FDA approval of zanidatamab for patients with HER2-positive metastatic biliary tract cancer.

James J. Harding, MD, discusses the significance of the FDA approval of zanidatamab for pretreated, unresectable or metastatic HER2+ biliary tract cancer.

Zanidatamab is a HER2-targeted bispecific antibody that binds to two non-overlapping HER2 domains and crosslinks neighboring HER2 proteins. In the primary analysis of the phase 2b HERIZON-BTC-01 trial (NCT04466891), after a median follow-up of 12.4 months, zanidatamab showed encouraging antitumor activity with rapid and durable responses and a manageable safety profile in patients with previously treated HER2+ BTC.

James Harding, MD, discusses the rationale for targeting FGFR2 in patients with cholangiocarcinoma and biliary tract cancers.

James Harding, MD, discusses the management of immune-related adverse effects in patients with advanced biliary tract cancer.

James Harding, MD, discusses future directions in the treatment of patients with advanced biliary tract cancer.

James Harding, MD, discusses key trials contributing to the evolution of frontline chemoimmunotherapy approaches in advanced biliary tract cancer.

James J. Harding, MD, discusses the prevalence of TSC1 and TSC2 mutations in gastrointestinal cancer, and the need to develop a standard-of-care treatment for patients with these genetic alterations.

James J. Harding, MD, discusses the results of the ongoing, phase 2 SUMMIT basket trial in HER2-mutant advanced biliary tract cancers.

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

James J. Harding, MD, discusses the goal of the phase III IMbrave150 trial in hepatocellular carcinoma (HCC).